SURGICAL SCISSORS FS-3L-1Recalls & reported problems
Olympus Medical Systems Corp. · FS-3L-1 REUS. SURGICAL SCISSORS · Class 1
Data updated Oct 16, 2026 from official FDA records · Editorial policy
- Adverse event reports
- 1
- Deaths reported
- 0
- Injuries reported
- 1
- Recalls naming it
- 0
Summary
The FDA's MAUDE database contains 1 adverse event report that list this exact device (DI 04953170033377), received between Nov 21, 2023 and Nov 21, 2023 — classified as 1 injury.
Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 16, 2026.
Reports received per month
Most reported problems
Device problems
- Adverse Event Without Identified Device or Use Problem1
Patient problems
- Hemorrhage/Blood Loss/Bleeding1
- Pancreatitis1
- Unspecified Hepatic or Biliary Problem1
Recent adverse event reports
The 1 most recent of 1 reports, in the reporter's own words as published by the FDA.
InjuryNov 21, 2023Adverse Event Without Identified Device or Use Problem; Adverse Event Without Identified Device or Use Problem
OLYMPUS REVIEWED THE FOLLOWING LITERATURE TITLED "ENDOSCOPIC INTERNALIZATION BY CUTTING VERSUS REMOVAL OF THE ENDOSCOPIC TRANSPAPILLARY NASO-GALLBLADDER DRAINAGE TUBE IN PREOPERATIVE MANAGEMENT OF ACUTE CHOLECYSTITIS: A RETROSPECTIVE MULTICENTER COHORT STUDY." ABSTRACT BACKGROUND: ENDOSCOPIC TRANSPAPILLARY NASO-GALLBLADDER DRAINAGE (ENGBD)HAS BEEN REPORTED TO BE AN EFFECTIVE TREATMENT OPTION FOR ACUTE CHOLECYSTITIS. AT OUR INSTITUTION, ENGBD WAS FIRST PLACED FOR EXTERNAL FISTULA MANAGEMENT, AND ENDOSCOPIC INTERNALIZATION BY CUTTING WAS PERFORMED, SHIFTING TO ENDOSCOPIC TRANSPAPILLARY GALLBLADDER STENTING (EGBS) AFTER IMPROVEMENT OF CHOLECYSTITIS. HOWEVER, THERE HAS BEEN NO COMPARATIVE STUDY TO DEFINE WHICH PREOPERATIVE MANAGEMENT IS BETTER: CONVERTING ENGBD TO EGBS OR REMOVING ENGBD. THE STUDY AIMED TO COMPARE THE INCIDENCE RATE OF THE LATE ADVERSE EVENTS (AES) RELATED TO BILIARY SYSTEM BETWEEN SHIFTING FROM ENGBD TO EGBS AND REMOVAL OF ENGBD. METHODS: WE RETROSPECTIVELY STUDIED 122 PATIENTS WHO UNDERWENT ENGBD FOR ACUTE CHOLECYSTITIS BETWEEN JANUARY 2010 AND OCTOBER 2022. THE PATIENTS WERE DIVIDED INTO TWO GROUPS: THE CUTTING GROUP (CONVERTING ENGBD TO EGBS) AND THE REMOVAL GROUP
Patient problems: Hemorrhage/Blood Loss/Bleeding; Pancreatitis; Unspecified Hepatic or Biliary Problem
MAUDE report 18185597 ↗
Other FORCEPS, BIOPSY, NON-ELECTRIC devices
- Radial Jaw 4 M00513410Boston Scientific Corporation · FORCEPS, BIOPSY, NON-ELECTRIC1 recall24 reports
- Radial Jaw 4 M00513330Boston Scientific Corporation · FORCEPS, BIOPSY, NON-ELECTRIC1 recall19 reports
- Radial Jaw 4 M00513400Boston Scientific Corporation · FORCEPS, BIOPSY, NON-ELECTRIC1 recall16 reports
- NA 8736685Richard Wolf GmbH · FORCEPS, BIOPSY, NON-ELECTRIC1 recall15 reports
- NA 828051Richard Wolf GmbH · FORCEPS, BIOPSY, NON-ELECTRIC1 recall6 reports
- Radial Jaw 4 M00513320Boston Scientific Corporation · FORCEPS, BIOPSY, NON-ELECTRIC1 recall3 reports
- Radial Jaw 4 M00513360Boston Scientific Corporation · FORCEPS, BIOPSY, NON-ELECTRIC1 recall2 reports
- NA 8735685Richard Wolf GmbH · FORCEPS, BIOPSY, NON-ELECTRIC1 recall1 report
Sources and updates
- Device record: FDA GUDID, file dated Oct 13, 2026 · View this device in AccessGUDID ↗
- Adverse event reports: FDA MAUDE, file dated Oct 14, 2026 · each report above links to its original FDA record
- Recalls: FDA Medical Device Recalls, file dated Oct 16, 2026
- Page last rebuilt: Oct 16, 2026. Data downloaded through openFDA, which notes it is not validated for clinical or regulatory use.
How reports and recalls are matched · Editorial policy · Report an error on this page